|
|
SPARTA, N.J. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead
|
|
|
|
-- Executing broad reach television advertising to support the launch of VAZALORE -- -- Media campaign reach matches extensive distribution at retailers -- SPARTA, N.J. , Aug. 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company
|
|
|
|
--Walmart, Walgreens, Rite Aid, CVS and many other retailers placing VAZALORE on shelves later this month-- --VAZALORE launch inventory manufactured and currently shipping to retailers across the country-- SPARTA, N.J. , Aug. 06, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc.
|
|
|
|
Shelf space for all three SKUs of VAZALORE is reserved with “Coming Soon” shelf placeholders SPARTA, N.J. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected
|
|
|
|
-- ‘Coming Soon’ placeholders for all three SKUs of VAZALORE to be positioned prominently on shelves -- SPARTA, N.J. , July 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and
|
|
|
|
SPARTA, N.J. , July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products
|
|
|
|
-- Shelf space for all three SKUs of VAZALORE is being reserved with ‘Coming Soon’ shelf placeholders -- SPARTA, N.J. , July 19, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and
|
|
|
|
-- “Coming Soon” shelf placeholders, already on store shelves to reserve space for VAZALORE -- SPARTA, N.J. , July 12, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected
|
|
|
|
SPARTA, N.J. , June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products
|
|
|
|
– VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsules, gain FDA approval – – Company secured $71.4 million of gross proceeds in an underwritten public offering of common stock for the launch of VAZALORE – – VAZALORE’s U.S. commercial launch on track for third quarter
|
|
